ERBB2 and triple-negative breast carcinoma: Current guidelines recommend neoadjuvant therapy for patients with ≥ cT2 or cN(+) luminal-type breast cancer and ≥ cT1c, cN0 human epidermal growth factor receptor 2 (HER2)-positive or triple-negative breast cancer (TNBC) [9].